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Abstract This study assessed the safety and preliminary
efficacy of the interleukin-1 receptor antagonist anakinra in
patients with polyarticular-course juvenile rheumatoid
arthritis (JRA). Eighty-six patients entered a 12-week
open-label run-in phase (1 mg/kg anakinra daily,
≤100 mg/day). Fifty responders were randomized to
anakinra or placebo in a 16-week blinded phase, followed
by a 12-month open-label extension (N=44). Due to low
enrollment, the primary endpoint was changed from
efficacy to safety. The incidence and nature of adverse
events were similar across all study phases, with the
exception of injection site reactions, which were mild to
moderate and decreased with time. Anakinra produced a
nonsignificant (P=0.11) reduction in disease flares com-
pared with placebo. When normalized to 1 mg/kg dose,
anakinra plasma concentrations were similar to values in
adult patients with rheumatoid arthritis. These results
indicate that anakinra 1 mg/kg once daily (≤100 mg/day)
is safe and well tolerated in patients with JRA.
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Introduction
Juvenile rheumatoid arthritis (JRA) is the most common
rheumatic disease of childhood [1–4] and can be associated
with uveitis, bone loss, reduced quality of life, and
increased mortality [1, 5–8]. Biologic agents provide a
targeted approach to the treatment of JRA, aimed at
preventing cytokine-mediated inflammation. Increased pro-
duction of the proinflammatory cytokine interleukin-1 (IL-
1) has been implicated in the pathogenesis of rheumatoid
arthritis (RA) [9, 10]. A number of publications also
support the role of IL-1 in JRA of different onset types
[11–14]. Consequently, the IL-1 receptor antagonist (IL-1ra)
has been investigated as a therapeutic option to reduce the
disease activity and joint damage caused by IL-1 [15].
Anakinra, a recombinant IL-1ra, has demonstrated
efficacy in reducing the symptoms of RA (alone or in
combination with methotrexate) in randomized controlled
trials in adults [16–18] and in small uncontrolled studies of
children with JRA [19, 20]. Treatment of RA patients with
anakinra has resulted in decreased radiographic progression
and beneficial effects on disease activity. Historically, JRA
therapy decisions have been guided by effective therapeutic
strategies employed in treating adult RA. Traditional therapies
such as disease-modifying antirheumatic drugs (DMARDs)
may not adequately control disease progression in JRA, and
their use is often limited by adverse events and significant
toxicities [21]. New treatment options are needed to improve
outcomes in JRA patients. In this current study, we inves-
tigated the safety of daily subcutaneous (SC) injections of
anakinra in patients with polyarticular-course JRA.
Materials and methods
Patients
This study was conducted in compliance with principles of
the US Food and Drug Administration and International
Conference on Harmonisation Good Clinical Practice
regulations/guidelines. The study was approved by the
Independent Ethics Committee/Institutional Review Board
of each study site, and all patients or guardians provided
written informed consent. Patients presenting with poly-
articular-course JRA, independent of onset, were eligible
for enrollment. Patients were required to have ≥5 swollen
joints due to active arthritis (not bony overgrowth) and
three joints with limitation of motion at screening and the
day 1 visit. Patients were between 2 and 17 years of age,
with a minimum weight of 10 kg. Children were to be on a
stable dose of methotrexate for 6 weeks before study entry
and not receiving biologic therapy within 4 weeks of
initiating study drug. The methotrexate dose was kept
stable during the open-label and blinded phases of the trial
(minimum dose of 10 mg m−2 wk−1 and a maximum dose
of 40 mg/wk). If administered, doses for nonsteroidal anti-
inflammatory drug (NSAID) therapy and oral corticoste-
roids (≤10 mg/day or 0.2 mg kg−1 day−1 of prednisone) had
to be kept stable for 4 weeks before the first dose of
anakinra and during the course of the trial.
A negative pregnancy test was required for females of
childbearing potential. Other exclusion criteria included the
following laboratory values: alanine aminotransferase or
aspartate aminotransferase >2.0 times the upper limit of
normal, creatinine >1.5 times the upper limit of normal,
white blood cell count <2.0×109/L, neutrophil count <1.5×
109/L, or a platelet count of <150×109/L. Children
receiving treatment with a DMARD other than methotrexate
could not participate in the study nor could patients
receiving intra-articular or systemic corticosteroid injections
within 4 weeks before study entry. Patients with clinically
significant systemic disease, such as hepatic, renal, neuro-
logical, endocrine, cardiac, gastrointestinal (except NSAID-
induced gastrointestinal problems), or hematological disease
or presence of symptoms of systemic disease such as
intermittent fever, rash, hepatosplenomegaly, or pericarditis,
within 24 weeks of the first dose of anakinra, were also
excluded.
Study design
This was a randomized, multicenter, blinded, placebo-
controlled study with an open-label run-in period, followed
by an open-label extension study (Fig. 1) to evaluate the
efficacy and safety of daily SC injections of anakinra in the
treatment of JRA (ClinicalTrials.gov # NCT00037648).
However, because of good responses to anti-tumor necrosis
factor-α therapy among patients with JRA and the desire of
patients and their families to avoid daily injections,
enrollment was not sufficient to meet sample size require-
ments (n=204) that could adequately power, at 80% or
higher, the efficacy analyses. Study objectives were
amended primarily to assess the safety of anakinra, with
an adjusted enrollment goal of 50 patients. Efficacy
analyses were performed to meet obligations under the US
Postmarketing Commitment and Pediatric Research Equity
Act. The study was conducted at 17 sites in the USA,
Canada, Australia, New Zealand, and Costa Rica from July
2000 to February 2004.
Patients received 12 weeks of open-label treatment with
anakinra 1 mg/kg daily, up to a maximum daily adminis-
tration of 100 mg/day by SC injection. Thereafter, patients
meeting the definition of responder (American College of
Rheumatology’s JRA Core Set Criteria) were randomly
assigned (1:1 ratio) to blinded doses of placebo or anakinra
for an additional 16 weeks. A responder was defined as
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having a ≥30% improvement in three of any six JRA Core
Set Criteria variables and with worsening by ≥30% in no
more than one of the remaining variables [22]. JRA Core
Set Criteria include the following: physician global assess-
ment of disease activity, patient/parent assessment of
disease activity, Childhood Health Assessment Question-
naire (CHAQ), number of joints with active arthritis,
number of joints with limited range of motion, and
erythrocyte sedimentation rate (ESR).
Patients who experienced disease flare during the
blinded phase were removed from the primary study but
had the option to switch arms (if on “blinded” placebo then
switched to “blinded” anakinra, and if on “blinded”
anakinra then switched to “blinded” placebo) and continue
blinded treatment. Disease flares were defined as (1) ≥30%
worsening in at least three of the six JRA Core Set Criteria
with improvement in ≤1 of the remaining six JRA Core Set
Criteria or (2) a change in at least two active joints or a
worsening by at least two units (based on a 0–10 scale) on
either the global assessments or the visual analog scale.
Patients had the option to continue anakinra therapy in the
open-label extension after the blinded phase. Assessments
were conducted at baseline, weeks 2 and 4, and every
4 weeks thereafter in the initial study and then every
3 months in the extension study for up to 12 months.
Study drug
Study drug was supplied in single-use vials of 100 mg/mL
and was required to be administered once daily by single
SC injection by a parent, guardian, caregiver, or the patient,
all of whom were instructed regarding the proper injection
technique. The placebo formulation was the same but
without anakinra. Study drug was administered at approx-
imately the same time each day in the upper thigh, upper
arm, or abdomen (rotating injection sites each day).
Study endpoints
The primary endpoint, safety, was assessed by evaluation of
the incidence of treatment-emergent adverse events (includ-
ing serious adverse events and infectious episodes) and
laboratory values. Immunogenicity was assessed by the
proportion of patients testing positive for IL-1ra antibodies
by immunoassay and for neutralizing capabilities by cell-
based bioassay. A screening biosensor immunoassay
(Biacore, Piscataway, NJ, USA) was used to test for
antibody formation to anakinra (at screening, day 1,
week 12, and week 28 or on early termination), and
positive samples were retested for neutralizing antibodies
using a bioassay. Vital signs, blood chemistries, detection
of IL-1ra antibodies, adverse events, concomitant medica-
tions, emergency room visits and/or hospitalizations, and
injection site reactions (ISRs) were evaluated throughout
the initial open-label phase, the blinded phase, and the
extension study.
Secondary endpoints included measures of efficacy and
pharmacokinetics. The primary efficacy endpoint was the
proportion of patients with disease flares in the 16-week
blinded phase. Other efficacy assessments included time to
disease flare and changes in the JRA core components at
week 28. Pharmacokinetic assessments were conducted at
screening; day 1; and weeks 2, 4, 8, 12, 16, 20, 24, and 28
or early termination to characterize a population profile.
Dosing times for each study patient were recorded only on
the initial day-1 dose. Consequently, intervals between the
time of daily administration of anakinra and the time when
blood would be obtained for laboratory testing were not
known. Plasma anakinra concentrations were normalized
(adjusted) to a daily dose of 1 mg/kg or a fixed dose of
100 mg, and exposure was compared with a previous study
in adults with RA [23–25]. Normalization was deemed
appropriate because anakinra exhibits linear clearance. To
normalize concentrations to a 1 mg/kg dose for the JRA and
adult RA studies, plasma anakinra concentrations were
divided by the mg/kg dose, and the dose in milligrams was
divided by the patient’s weight to obtain the dose in
milligrams per kilogram. To normalize concentrations to a
100-mg dose, the concentrations were divided by the total
dose in milligrams and then were multiplied by 100.
Efficacy and pharmacokinetics were not analyzed in the
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Fig. 1 Study design. *Patients
switched treatment arms if they
elected to continue
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Statistical analyses
Safety results were summarized for all patients who
received at lease one dose of study medication. Descriptive
statistics were used to summarize all data. The proportion
of randomized patients with disease flares during the
blinded phase in the two treatment groups (anakinra vs
placebo) was compared using the Fisher exact test with a
two-tailed significance level of 0.05. The analysis of time-
to-disease flare from randomization during the 16-week
blinded phase in the intent-to-treat subset was assessed
using the log-rank test (P value=0.05).
Results
Patients
Patient disposition throughout the three phases of the trial is
shown in Fig. 2. Eighty-six patients entered the initial open-
label treatment phase, and 50 patients responded to
anakinra therapy and entered the blinded phase of the
study; 27 patients (31%) were nonresponders. The most
common reasons for early withdrawal from the open-label
phase were adverse events (n=4) and withdrawal of patient
consent (n=3). Thirty-one patients completed the blinded
phase. The number of patients who withdrew from the
blinded phase was lower in the anakinra group (n=6)
compared with the placebo group (n=13); most patients
withdrew because of disease flare (anakinra, n=4; placebo,
n=10). A total of 44 patients were enrolled in the extension
study (those who completed the blinded phase [n=30] and
those who were terminated from the blinded phase because
of disease flare and then elected to enroll in the extension
[n=14]); most patients discontinued for reasons other than
adverse events (e.g., consent withdrawn [n=3], administra-
tive decision [n=2], or lost to follow-up [n=2]).
Baseline demographics and clinical characteristics of
patients entering the 12-week open-label phase, the 16-
week double-blind phase, and the extension study were
similar among the groups presented (Table 1). Most patients
were females, had polyarticular-onset JRA, and had active
disease despite methotrexate therapy. In the double-blind
phase, the mean duration of JRA was similar in patients
receiving anakinra (3.9 years) or placebo (4.2 years). In
addition, 76% of patients receiving placebo and 88% of
patients receiving anakinra were taking methotrexate, 44%
and 76%, respectively, were taking corticosteroids, 16%
and 20%, respectively, were taking other DMARDs, and
4% and 0%, respectively, were taking NSAIDs.
Safety
Treatment-emergent adverse events in all phases of the
study are presented in Table 2. Adverse events, except
ISRs, were similar in nature and occurred with similar
frequency in all phases. In the open-label phase, the most
common adverse events were ISRs (74%), upper respirato-
ry infections (23%), and headache (22%); five events led to
withdrawal of four patients (ISR [n=3], synovitis [n=1],
and dysuria [n=1]). Injection site pain was experienced by
29 patients (34%). The most common adverse event
causing withdrawal in the open-label phase was ISRs (three
patients; 3.5%). In the blinded phase, the three most
common adverse events were ISRs (12% in each group),
upper respiratory infections (20% of placebo-treated
patients and 16% of anakinra-treated patients), and head-
ache (4% of placebo-treated patients and 24% of anakinra-
treated patients). No patients withdrew because of an
adverse event in the blinded phase. In the extension study,
the most common adverse events were arthralgia (23%),
fever (21%), and abdominal pain (16%). Three (7%)
patients withdrew because of an adverse event: one patient
with JRA flare, one patient with worsening of JRA, and one
patient with nephrosis.
Three serious adverse events were reported in the open-
label phase; however, none were considered by the
physician investigator to be related to study medication.
No serious adverse events were reported in the blinded
phase. In the extension trial, two patients had a total of

































Fig. 2 Patient disposition
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considered related to study medication (withdrew, see
above) and one patient with hepatitis and a viral infection,
both considered not related to study medication. The patient
who experienced nephrosis was a 16-year-old female who
developed bilateral ankle and lower leg edema, hyperten-
sion, and proteinuria approximately 3 weeks into the open-
label extension phase of the trial and discontinued anakinra.
Infectious episodes were reported by 35 patients (41%)
in the open-label phase. One case was serious but not
considered by the investigator to be related to study
medication. In the blinded phase, nine (36%) patients
receiving anakinra and eight (32%) patients receiving
placebo reported infectious episodes, the most common of
which were upper respiratory infection and upper respira-
tory tract congestion. In the extension study, 16 (36%)
patients had an infectious episode; the most common
infectious events (reported in at least three patients) were
upper respiratory infection (four patients, 9%), fever (three
patients, 7%), and influenza-like symptoms (three patients,
7%). One event (hepatitis due to cytomegalovirus infection)
was considered to be serious but was not considered to be
related to study medication by the investigator.
In the open-label and blinded phases, laboratory changes
during anakinra therapy included transient neutropenia
(white blood cell count of 0.79×109/L on day 141 in one
patient that recovered to 1.0×109/L by the next study visit),
anemia (grade 3 based on World Health Organization
Toxicity Criteria [26]; moderate anemia 6.5–7.9 g/dL;
hemoglobin decrease in one patient reported on study
day 1 only [patient discontinued study on day 1 due to ISR
pain]), calcium toxicity (hypercalcemia [12.6–13.4 mg/dL],
or hypocalcemia [6.9–6.1 mg/dL], grade 3 or higher;
reported in one patient who had been taking a calcium
supplement prior to the increase), and hepatotoxicity (grade
3 [liver enzyme values 5.1–20 times normal]; elevated
alanine aminotransferase reported on day 15 in one patient
that did not lead to withdrawal, and no other elevations
were reported in this patient). Laboratory changes were not
associated with serious adverse events. Similar findings
were observed in the extension study, with the exception
that one finding (hepatotoxicity) was associated with a
serious adverse event (hepatitis and viral infection).
Immunogenicity data were available for 64 patients in
the open-label phase, 27 patients in the double-blind phase
(placebo, n=9; anakinra, n=18), and 44 patients in the
extension trial. In the open-label phase, 48 (75%) were
positive for non-neutralizing anti-IL-1ra antibodies, and
four (6%, all nonresponders) had neutralizing antibodies. In
the blinded phase, four (44%) placebo-treated patients and
13 (72%) anakinra-treated patients were positive for anti-
bodies by immunoassay; one patient taking placebo tested
positive for neutralizing antibodies. In the extension study,
36 (82%) had confirmed presence of anti-IL-1ra antibodies,
but none tested positive for neutralizing antibodies.
















Female 63 (73) 18 (72) 17 (68) 31 (70)
Male 23 (27) 7 (28) 8 (32) 13 (30)
Race, n (%)
White 46 (53) 15 (60) 13 (52) 25 (57)
Black 5 (6) 0 (0) 3 (12) 2 (5)
Hispanic 29 (34) 10 (40) 8 (32) 16 (36)
American Indian or Alaska Native 3 (3) 0 (0) 1 (4) 1 (2)
Asian 1 (1) 0 (0) 0 (0) 0 (0)
Other 2 (2) 0 (0) 0 (0) 0 (0)
Mean age, year (range) 12 (3–17) 12 (4–17) 10 (3–17) 12 (4–18)
Mean weight, kilogram (range) 40 (12–101) 44 (16–101) 36 (12–98) 44 (13–105)
Mean duration of JRA, year (range) 4.7 (1–16) 4.2 (1–16) 3.9 (1–11) 4.8 (1–7)
Type of arthritis at onset, n (%)
Polyarticular 62 (72) 19 (76) 14 (56) 29 (66)
Systemic 15 (17) 2 (8) 9 (36) 10 (23)
Pauciarticular 9 (10) 4 (16) 2 (8) 5 (11)
JRA-related medications
Corticosteroids 50 (58) 11 (44) 19 (76) 27 (61)
DMARDs 25 (29) 4 (16) 5 (20) 8 (18)
Methotrexate 67 (78) 19 (76) 22 (88) 38 (86)
NSAIDs 2 (2) 1 (4) 0 (0) 0 (0)
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Efficacy
Compared to baseline, a majority of patients (58%)
achieved a ≥30% improvement in the JRA Core Set
Criteria and were considered responders in the 12-week
open-label portion of the trial. The highest percentage of
responders within a disease subset were those with systemic
onset (73%) compared with pauciarticular (67%) and
polyarticular (53%) onset. During the double-blind phase
of the trial, fewer patients treated with anakinra had disease
flares compared with patients receiving placebo at all time
points; at week 28, four (16%) anakinra patients (two of
nine with systemic and two of 14 with polyarticular disease
onset) and ten (40%) placebo patients (one of two with
systemic, one of four with pauciarticular, and eight of 19
with polyarticular disease onset) had a disease flare (not
significant by Fisher exact test [P=0.11]). Time to disease
flare was greater in patients receiving anakinra, nearly
reaching statistical significance (P=0.057 based on log-
rank test). Compared with the placebo group, patients
treated with anakinra demonstrated a slight progressive
improvement in mean change in CHAQ at week 28 (−0.25
vs 0.13). Patients in the anakinra group also had progres-
sive improvement in ESR through week 28 compared with
placebo (−2.21 vs 13.73 mm/h).
Pharmacokinetics
Individual concentration-time data for patients receiving
anakinra are shown in Fig. 3. With the daily anakinra dose
normalized to 1 mg/kg, the range of concentrations was
comparable to that observed in adults with RA [23–25].
When the dosage was normalized to 100 mg/day, a trend of
higher concentrations was observed compared with adult
RA patients. Higher concentration ranges were recorded in
children with lower body weight. The mean normalized (to
a 1-mg/kg dose) plasma concentrations of anakinra were
182, 259, and 194 ng/mL in JRA patients aged 3 to 6, 7 to
12, and 13 to 17 years, respectively, compared with a mean
normalized plasma concentration of 221 ng/mL in adult RA
patients. When normalized to a 100-mg daily dose of
anakinra, the mean plasma concentrations were 1110, 717
Table 2 Most frequent treat-
ment-emergent adverse events
in ≥5 patients in any treatment
group by body system category
CNS Central nervous system
a This number in the overall
adverse event data differs from
that in the infectious episodes
data because not all adverse













Number of patients reporting adverse events 80 (93) 18 (72) 17 (68) 30 (68)
Application site 64 (74) 3 (12) 3 (12) 2 (5)
Ecchymosis 12 (14) 1 (4) 1 (4) 0
Edema 9 (11) 0 1 (4) 0
Erythema 31 (36) 1 (4) 2 (8) 0
Inflammation 8 (9) 1 (4) 0 1 (2)
Pain 29 (33) 0 0 2 (5)
Pruritus 26 (30) 1 (4) 1 (4) 0
Rash 14 (16) 0 0 0
Reaction 10 (12) 0 1 (4) 0
Body as a whole 26 (30) 5 (20) 9 (36) 14 (32)
Fever 14 (16) 2 (8) 3 (12) 9 (21)
Pain 5 (6) 2 (8) 0 4 (9)
CNS 21 (24) 4 (16) 6 (24) 8 (18)
Headache 19 (22) 1 (4) 6 (24) 6 (14)
Gastrointestinal 29 (34) 5 (20) 8 (32) 13 (30)
Diarrhea 7 (8) 0 3 (12) 2 (4.5)
Nausea 7 (8) 0 0 2 (4.5)
Pain, abdominal 15 (17) 2 (8) 3 (12) 7 (16)
Vomiting 6 (7) 0 2 (8) 1 (2)
Musculoskeletal 26 (30) 9 (36) 7 (28) 16 (36)
Arthralgia 11 (13) 4 (16) 1 (4) 10 (23)
Pain, limb 6 (7) 4 (16) 3 (12) 5 (11)
Respiratory 36 (42) 7 (28) 8 (32) 15 (34)
Cough 5 (6) 0 0 3 (7)
Infection, upper respiratorya 20 (23) 5 (20) 4 (16) 5 (11)
Sore throat 5 (6) 0 2 (8) 4 (9)
Skin and appendages 23 (27) 7 (28) 2 (8) 9 (21)
Rash 9 (11) 3 (12) 0 (0) 4 (9)
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and 420 ng/mL in JRA patients aged 3 to 6, 7 to 12, and 13
to 17 years, respectively, compared with a mean normalized
plasma concentration of 319 ng/mL in adult RA patients.
Discussion
The findings from this study indicate that the short-term
safety profile of anakinra in juvenile patients is similar to
that reported for adults with RA in clinical trials. During the
blinded phase, the most common adverse events were ISRs,
headache, and upper respiratory infections. Adverse events
occurred with a similar incidence in patients receiving
anakinra or placebo. Across all phases of the study, few
adverse events were serious or led to study withdrawal.
Similar to other subcutaneously administered biologics,
ISRs appeared to be common with daily use of anakinra,
occurred early in the trial, and resolved over time. The
frequency of ISRs decreased in the double-blind period
compared with the open-label phase, which is consistent
with findings in adults in which ISRs were more common
with the initial period of dosing and transient in duration
[27]. In contrast, one patient (4%) receiving placebo
experienced headache as compared with six patients
(24%) who received anakinra. No patients withdrew from
the study owing to headache. Furthermore, it should be
noted that headache has been reported in up to 28% of
adolescent patients with JRA [28] and that the incidence of
headache in this study was consistent with this previous
report.
Considering the increased risk of infection associated
with rheumatic diseases [29] and biologic agents [30],
infectious episodes associated with anakinra therapy repre-
sent an important safety concern, particularly in children.
Infection rates in this study were low and generally
consistent with other trials evaluating anakinra in adults
with RA [27, 30]. In a 6-month randomized, placebo-
controlled, double-blind study followed by an open-label
phase for up to 3 years, only 8% (n=105) of adult RA
patients receiving anakinra (n=1346) experienced a serious
infection, with pneumonia being the most frequent [27]. In
adults, there were also three events of opportunistic
infection (atypical mycobacterial infection, histoplasmosis,
and candida esophagitis) occurring between 5 months to
2.5 years after initiating anakinra [27]. In a prospective
cohort study of RA patients (n=70) receiving anakinra for
up to 1 year, 13% of the patients experienced an infection,
two of which were considered serious [30]. In this present
study, the occurrence of serious infections during exposure
to anakinra was low. In the open-label phase, one patient
experienced severe impetigo, but this was not considered
by the investigator to be related to the study medication. No
serious infections were reported during the blinded phase,
and one patient in the extension phase reported a serious
viral hepatitis infection that was not considered related to
study medication. There were no reports of opportunistic
infections. These results are generally consistent with safety
data for other biologic therapy (etanercept) in JRA [31–33].
Although there are limited data regarding the efficacy of
anakinra in JRA, published reports suggest that anakinra
may reduce symptoms and joint damage in patients with
systemic-onset JRA [19, 20]. A recent study in 20 patients
with systemic-onset juvenile idiopathic arthritis reported
that anakinra was effective in some patients, with 50% and
25% of patients achieving 30% and 50% improvements,
respectively, in American College of Rheumatology (ACR)







































Fig. 3 Anakinra plasma
concentrations
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pedi core set criteria [34]. Recent data also support anakinra
as second-line therapy for systemic-onset juvenile idiopath-
ic arthritis, with six of seven patients from a case series in
the UK experiencing rapid early improvement in systemic
symptoms and joint disease [35]. Irigoyen et al. [19]
reported findings from a multicenter retrospective chart
review of systemic-onset JRA patients (n=7) receiving
anakinra. The majority of treated patients (six of seven)
experienced rapid (in as little as 2 weeks) improvement in
joint symptoms (as measured by reduction in active joints).
Pascual et al. [20] reported similar findings with significant
improvement (P=0.006 compared with baseline) in arthritis
symptoms (active joint count) at 2 months after initiation of
anakinra treatment in nine patients (aged 4–17 years) with
systemic-onset JRAwho were unresponsive to conventional
treatment. A post hoc analysis by subgroup in the current
analysis showed that two of nine systemic onset JRA
patients flared in the anakinra group and one of two flared
in the placebo group.
In addition, Pascual et al. [20] demonstrated that IL-1
gene expression is up-regulated in the peripheral blood
mononuclear cells of patients with active systemic onset
JRA, supporting the premise that IL-1 may be a mediator of
the inflammatory cascade of patients with active systemic-
onset JRA. Further support for the role of IL-1 in systemic-
onset disease in children comes from a recent analysis in
which complete responders to anakinra in patients with this
condition appear to be characterized by the presence of
distinct clinical features [36].
The results of the pharmacokinetic analyses demonstrat-
ed that weight-based dosing with 1 mg/kg SC daily
provides adequate anakinra exposure in children with
JRA. Plasma concentrations appeared to show a trend to
higher levels in JRA patients when normalized to a fixed
100-mg daily dose than observed in adults. However, when
normalized to a weight-based dose of 1 mg/kg, anakinra
concentrations were comparable to those in adults.
In summary, anakinra 1 mg/kg administered as a SC
injection once daily (up to a maximum of 100 mg/day) was
well tolerated in pediatric patients with JRA. Infection rates
were low, and no clinically significant abnormalities in
laboratory data were observed. Efficacy results were not
conclusive because of the small sample size. Pharmacoki-
netic assessments indicated that a daily dosage of 1 mg/kg
administered SC provided adequate exposure for the
treatment of JRA. Safety data from this study were consistent
with results from larger studies in adults and indicated that
anakinra was safe and well tolerated in patients with JRA.
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